Published in J Surg Oncol on April 01, 1998
Metastatic behavior in melanoma: timing, pattern, survival, and influencing factors. J Oncol (2012) 1.44
Sentinel lymph node biopsy in the management of patients with primary cutaneous melanoma: review of a large single-institutional experience with an emphasis on recurrence. Ann Surg (2001) 1.36
Current concepts of metastasis in melanoma. Expert Rev Dermatol (2008) 1.34
Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst (2010) 1.31
Primary staging and follow-up in melanoma patients--monocenter evaluation of methods, costs and patient survival. Br J Cancer (2002) 1.11
Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma. Mayo Clin Proc (2014) 1.06
Solitary dermal melanoma: beginning or end of the metastatic process? Ann Surg Oncol (2009) 0.97
Malignant melanoma of the skin: long-term follow-up and time to first recurrence. World J Surg (2011) 0.91
Histopathologic excision margin affects local recurrence rate: analysis of 2681 patients with melanomas < or =2 mm thick. Ann Surg (2005) 0.90
Is sentinel lymph node mapping indicated for isolated local and in-transit recurrent melanoma? Ann Surg (2003) 0.88
Variability in melanoma post-treatment surveillance practices by country and physician specialty: a systematic review. Melanoma Res (2012) 0.84
Prognostic factors of melanoma patients with satellite or in-transit metastasis at the time of stage III diagnosis. PLoS One (2013) 0.82
Parametric modeling of localized melanoma prognosis and outcome. J Biopharm Stat (2009) 0.78
Differentiation of cutaneous melanoma from surrounding skin using laser-induced breakdown spectroscopy. Biomed Opt Express (2015) 0.78
Long-term follow-up for melanoma patients: is there any evidence of a benefit? Surg Oncol Clin N Am (2015) 0.78
Tumor-infiltrating lymphocytes and mitotic index in metastatic melanoma as predictors of patient survival. Proc Natl Acad Sci U S A (2010) 0.76
A high proliferative index of recurrent melanoma is associated with worse survival. Oncology (2011) 0.75
Surgical resection plus biotherapy/chemotherapy improves survival of hepatic metastatic melanoma. World J Hepatol (2012) 0.75
An unusual presentation of recurring metastatic melanoma. J Surg Case Rep (2016) 0.75
Predictive factors for loco regional recurrence and distant metastasis following primary surgical treatment of cutaneous melanoma. Indian J Dermatol (2014) 0.75
Tumour mutation status and sites of metastasis in patients with cutaneous melanoma. Br J Cancer (2017) 0.75
A differentiation antigen of human NK and K cells identified by a monoclonal antibody (HNK-1). J Immunol (1981) 8.17
CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J Exp Med (1989) 4.19
A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol (1983) 3.80
Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol (1999) 3.74
Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol (2000) 3.42
Evidence for presence of an internal thiolester bond in third component of human complement. Proc Natl Acad Sci U S A (1980) 3.00
A multifactorial analysis of melanoma: prognostic histopathological features comparing Clark's and Breslow's staging methods. Ann Surg (1978) 2.94
Smoking and age-related macular degeneration: a review of association. Eye (Lond) (2005) 2.77
Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg (1996) 2.68
A multifactorial analysis of melanoma. II. Prognostic factors in patients with stage I (localized) melanoma. Surgery (1979) 2.65
Characterization of HNK-1+ (Leu-7) human lymphocytes. I. Two distinct phenotypes of human NK cells with different cytotoxic capability. J Immunol (1982) 2.63
The physiological breakdown of the third component of human complement. Mol Immunol (1980) 2.50
Tumor thickness as a guide to surgical management of clinical stage I melanoma patients. Cancer (1979) 2.41
Elective lymph node dissection in patients with primary melanoma of the trunk and limbs treated at the Sydney Melanoma unit from 1960 to 1991. J Am Coll Surg (1995) 2.38
Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol (2004) 2.36
Postnatal expansion of the natural killer and keller cell population in humans identified by the monoclonal HNK-1 antibody. J Exp Med (1982) 2.35
Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol (1997) 2.32
Improved staging of node-negative patients with intermediate to thick melanomas (>1 mm) with the use of lymphatic mapping and sentinel lymph node biopsy. Ann Surg Oncol (2001) 2.19
Short-term digital surface microscopic monitoring of atypical or changing melanocytic lesions. Arch Dermatol (2001) 2.15
The stoichiometry of polypeptide chains in the pyruvate dehydrogenase multienzyme complex of E. coli determined by a simple novel method. FEBS Lett (1975) 2.13
Desmoplastic and desmoplastic neurotropic melanoma: experience with 280 patients. Cancer (1998) 2.12
A comparison of prognostic factors and surgical results in 1,786 patients with localized (stage I) melanoma treated in Alabama, USA, and New South Wales, Australia. Ann Surg (1982) 2.09
A multifactorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node metastases (stage II). Ann Surg (1981) 2.09
Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg (1993) 2.08
Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Oncol (2001) 2.06
Omega 3 fatty acids for prevention and treatment of cardiovascular disease. Cochrane Database Syst Rev (2004) 2.05
Multimodality treatment of Merkel cell carcinoma: case series and literature review of 1024 cases. Ann Surg Oncol (2001) 2.03
Leu-11+ lymphocytes with natural killer (NK) activity are precursors of recombinant interleukin 2 (rIL 2)-induced activated killer (AK) cells. J Immunol (1985) 2.03
Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor. J Exp Med (1988) 1.98
Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol (1998) 1.92
Recent advances in the care of the patient with malignant melanoma. Ann Surg (1997) 1.92
Resection margins for melanoma. Aust N Z J Surg (1985) 1.92
Surface microscopy of pigmented basal cell carcinoma. Arch Dermatol (2000) 1.88
The nature of immune complexes in human cancer sera. J Immunol (1977) 1.88
A rational approach to the surgical management of melanoma. Ann Surg (1977) 1.88
Conventional TRAM flap versus free microsurgical TRAM flap for immediate breast reconstruction. Plast Reconstr Surg (1989) 1.87
Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. Melanoma Res (1995) 1.87
A major immunogen in Schistosoma mansoni infections is homologous to the heat-shock protein Hsp70. J Exp Med (1987) 1.79
Location of sentinel lymph nodes in patients with cutaneous melanoma: new insights into lymphatic anatomy. J Am Coll Surg (1999) 1.68
The prognostic significance of ulceration of cutaneous melanoma. Cancer (1980) 1.66
Sentinel node biopsy provides more accurate staging than elective lymph node dissection in patients with cutaneous melanoma. Ann Surg Oncol (2004) 1.64
Small-diameter malignant melanoma: a common diagnosis in New South Wales, Australia. J Am Acad Dermatol (1992) 1.64
Prophylactic lymph node dissection in clinical stage I cutaneous malignant melanoma: results of surgical treatment in 1319 patients. Br J Surg (1982) 1.62
Suppressor cell function of human granular lymphocytes identified by the HNK-1 (Leu 7) monoclonal antibody. J Immunol (1983) 1.60
Foreign bodies in the appendix. Report of eight cases and review of the literature. Arch Surg (1971) 1.55
Frequency and morphologic characteristics of invasive melanomas lacking specific surface microscopic features. Arch Dermatol (1996) 1.53
Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas. Cancer Res (1986) 1.50
Differentiation stages of human natural killer cells in lymphoid tissues from fetal to adult life. J Exp Med (1983) 1.48
Cranial irradiation after surgical excision of brain metastases in melanoma patients. Ann Surg Oncol (1996) 1.48
A multifactorial analysis of prognostic factors in patients with liver metastases from colorectal carcinoma. J Clin Oncol (1983) 1.46
A prospective phase II clinical trial of continuous FUDR regional chemotherapy for colorectal metastases to the liver using a totally implantable drug infusion pump. Ann Surg (1983) 1.45
Isolation and characterization of a membrane protein from rat erythrocytes which inhibits lysis by the membrane attack complex of rat complement. Biochem J (1992) 1.43
Can pathological complete response in the primary tumour following pre-operative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for sterilisation of pelvic lymph nodes, a low risk of local recurrence and the appropriateness of local excision? Int J Colorectal Dis (2005) 1.42
Corynebacterium parvum versus bacille Calmette-Guérin adjuvant immunotherapy of stage II malignant melanoma. J Clin Oncol (1991) 1.42
The prognostic significance of lymph node metastases after preoperative chemotherapy for locally advanced breast cancer. Arch Surg (1989) 1.41
What is a surgical oncologist? Ann Surg Oncol (1994) 1.40
Endocrine influences on survival from malignant melanoma. Cancer (1978) 1.40
How patient referral bias can confuse interpretation of clinical results: elective lymph node dissections at the Sydney Melanoma Unit. J Am Coll Surg (1995) 1.39
The needle biopsy should replace open excisional biopsy ... but will the surgeon's role in coordinating breast cancer treatment be diminished? Ann Surg Oncol (1995) 1.39
Prognostic histopathological factors in malignant melanoma. Pathology (1985) 1.39
Think melanoma. South Med J (1993) 1.39
Developments in surgical oncology--past, present, and future trends. Med J Aust (1992) 1.38
Atrial fibrillation control and cardioversion. Lancet (2001) 1.38
Characterization of HNK-1+ (Leu-7) human lymphocytes. II. Distinguishing phenotypic and functional properties of natural killer cells from activated NK-like cells. J Immunol (1982) 1.38
The effects of surgical treatment on survival and local recurrence of cutaneous malignant melanoma. Cancer (1992) 1.38
Immunological effects of solarium exposure. Lancet (1983) 1.38
Human C1 inhibitor: improved isolation and preliminary structural characterization. Biochemistry (1983) 1.37
Isolation and partial characterization of the human homologue of Thy-1. J Exp Med (1980) 1.34
Structure of a soluble, glycosylated form of the human complement regulatory protein CD59. Structure (1994) 1.34
An improved purification procedure for the third component of complement and beta 1H globulin from human serum. Mol Immunol (1979) 1.34
Surgery for abdominal metastases of cutaneous melanoma. World J Surg (2001) 1.33
Physiologic inactivation of fluid phase C3b: isolation and structural analysis of C3c, C3d,g (alpha 2D), and C3g. J Immunol (1984) 1.32
Role of matrix metalloproteinases in colorectal carcinogenesis. Ann Surg (2001) 1.30
Do nodal metastases from cutaneous melanoma of the head and neck follow a clinically predictable pattern? Head Neck (2001) 1.30
Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol (1998) 1.29
Interval nodes: the forgotten sentinel nodes in patients with melanoma. Arch Surg (2000) 1.29
Involvement of the cytotoxic/suppressor T-cell subset in liver tissue injury of patients with acute and chronic liver diseases. Gastroenterology (1983) 1.26
Subungual melanoma of the hand. J Hand Surg Am (1996) 1.26
Experience with 998 cutaneous melanomas of the head and neck over 30 years. Am J Surg (1991) 1.26
Survival following locoregional recurrence after breast conservation therapy for cancer. Ann Surg (1990) 1.25
The influence of surgical margins and prognostic factors predicting the risk of local recurrence in 3445 patients with primary cutaneous melanoma. Cancer (1985) 1.24
Previous pregnancy as a protective factor against death from melanoma. Lancet (1977) 1.23
Suppression of immunoglobulin synthesis by lymphocyte subpopulations in patients with Crohn's disease. Gastroenterology (1984) 1.22
Low natural-killer-cell activity in familial melanoma patients and their relatives. Br J Cancer (1979) 1.22
Breast cancer screening knowledge, attitudes, and practices among Korean American women. Oncol Nurs Forum (2001) 1.22
Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma. J Invest Dermatol (1991) 1.22
Local recurrence in malignant melanoma: long-term results of the multiinstitutional randomized surgical trial. Ann Surg Oncol (1996) 1.21
Thin malignant melanomas and recurrence potential. Arch Surg (1987) 1.21
Sequence determination of the thiolester site of the fourth component of human complement. Proc Natl Acad Sci U S A (1981) 1.19
Cigarette smoking and thyroid eye disease: a systematic review. Eye (Lond) (2006) 1.19
Selective lymphadenectomy: emerging role for lymphatic mapping and sentinel node biopsy in the management of early stage melanoma. Semin Surg Oncol (1993) 1.19